Fulcrum Launches Phase 2b Trial of Losmapimod for FSHD
Fulcrum Therapeutics announced it has launched ReDUX4, a Phase 2b clinical trial designed to assess the safety and efficacy of losmapimod, an investigational treatment for facioscapulohumeral muscular dystrophy (FSHD) in patients with a genetically confirmed diagnosis of FSHD. The Phase 2b ReDUX4 trial (NCT04003974) is recruiting…